793 abstracts found.



Results filter

Master protocols in lung cancer

Year:

Session type: ,

Fred Hirsch1

1University of Colorado Cancer Center, Colorado, USA


Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From BATTLE to Master Protocols to Immunotherapy

Year:

Session type:

Roy S. Herbst1,2

1Yale Cancer Center, New Haven, CT, USA,2Yale School of Medicine, New Haven, CT, USA,3Smilow Cancer Hospital, New Haven, CT, USA


Germline genomics and predisposition to serious adverse drug reactions with anti-cancer drugs

Year:

Session type: ,

Munir Pirmohamed1

1University of Liverpool, Liverpool, UK


Interventional genetics

Year:

Session type: ,

John Burn1

1Newcastle University, Newcastle, UK




Gut microbiota and anti-cancer immune responses 

Year:

Session type: ,

Laurence Zitvogel1

1Institut Gustave Roussy and INSERM, Villejuif, France


Evolutionary tales in leukaemia

Year:

Session type: ,

Mel Greaves1

1The Institute of Cancer Research, Sutton, UK


Primary prevention, symptomatic diagnosis and screening: roles for general practice and primary care

Year:

Session type: ,

David Weller1

1University of Edinburgh, Edinburgh, UK


What are the treatment-related preferences of patients with advanced cancer? A discrete choice experiment.

Year:

Session type:

Mark O’Kane1

1University of Leeds, Leeds, UK


Targeting tumour angiogenesis by targeting Angiopoietin/Tie signalling: from vascular regression over vascular normalisation to stromal reprogramming therapies

Year:

Session type: ,

Hellmut G. Augustin1

1Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance); Vascular Biology and Tumour Angiogenesis, Medical Faculty Mannheim (CBTM), Heidelberg University; Germ, Germany, Germany


T Cell Engineering as Therapy for Cancer and HIV: Our Synthetic Future

Year:

Session type: ,

Carl June1

1University of Pennsylvania, Philadelphia, PA, USA


Heterogeneity, drug resistance and clonal evolution of colorectal cancers

Year:

Session type: ,

Alberto Bardelli1

1University of Toringo, Turin, Italy


Linking diet, nutrition and physical activity to cancer: a systematic review framework for integrating evidence from human, animal and other mechanistic studies

Year:

Session type:

Sarah Lewis1

1University of Bristol, Bristol, UK


Cell cycle checkpoint rewiring after p53 loss blocks G1/S and G2/M progression through kinase control of a single RNA-binding protein  

Year:

Session type:

Michael B. Yaffe1

1Koch Institute for Integrative Cancer Biology, Cambridge, USA




Genetic dissection of tumor development, therapy response and resistance in mouse models of BRCA1-deficient breast cancer

Year:

Session type: ,

Jos Jonkers1

1Netherlands Cancer Institute, Amsterdam, The Netherlands


Epigenetic Targets in Cancer

Year:

Session type: ,

Kristian Helin1

1University of Copenhagen, Copenhagen, Denmark




Radium-223 for prostate cancer bone metastases: How research can change clinical practice

Year:

Session type: ,

Joe O’Sullivan1,2

1Queen’s University Belfast, Belfast, Northern Ireland, UK,2Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK


CReST trial: addressing surgical management of emergency oncology admissions and the role of randomised trials

Year:

Session type: ,

James Hill1

1Manchester Royal Infirmary, Manchester, UK,2Manchester Academic Health Science Center, Manchester, UK


miRNA as biomarkers for early lung cancer detection

Year:

Session type: ,

gabriella sozzi1

1Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy


Electronic Cigarettes – Are They Safe?

Year:

Session type: ,

Maciej Goniewicz1

1Roswell Park Cancer Institute, Buffalo, NY, USA




Molecularly Targeted Radiation Therapy: Towards Individualised Treatment 

Year:

Session type: ,

Katherine Vallis1

1CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK




Molecular biomarkers: are they so much better than traditional risk factors and simple biomarkers?

Year:

Session type: ,

Peter Sasieni1

1Queen Mary University of London, London, UK


Ovarian Cancer screening – update from UK trials

Year:

Session type: ,

Usha Menon1

1University College London, London, England, UK


opportunistic salpingectomy: development and implementation of an ovarian cancer prevention campaign

Year:

Session type:

Jessica McAlpine1

1Department of Gynaecology and Obstetrics, University of British Columbia, Vancouver, Canada




Epigenetic reprogramming in mammalian development

Year:

Session type: ,

Wolf Reik1

1Babraham Institute, Cambridge, UK,2Centre for Trophoblast Research, University of Cambridge, Cambridge, UK,3Wellcome Trust Sanger Institute, Cambridge, UK


Engineering T cells for cancer therapy: progress and challenges

Year:

Session type:

Carl June1

1Perelman School of Medicine at thr University of Pennsylvania, Philadelphia, USA


Progressing radiotherapy-drug combinations towards early phase clinical trials

Year:

Session type: ,

Anthony Chalmers1

1University of Glasgow, Glasgow, UK


Is late diagnosis of cancer real and if so what can we do about it?”

Year:

Session type: ,

Harpal Kumar1

1Cancer Research UK, London, UK




Epigenetic Targets for Cancer Drug Discovery: Bromodomains and Beyond

Year:

Session type: ,

Mark Bunnage1

1Pfizer, Cambridge, MA, USA


Probing the transcriptional consequences of Ras and Rho activation

Year:

Session type: ,

Richard Treisman1,2

1Cancer Research UK London Research Institute, London, UK,2Francis Crick Institute, London, UK


Population based approach(es) to genetic testing for ovarian cancer prevention

Year:

Session type:

Ranjit Manchanda1,2

1Barts Cancer Institute, Queen Mary University of London, London, UK,2Bartshealth NHS Trust, London, UK


Cardiovascular toxicity in paediatric cancer treatment

Year:

Session type: ,

Steven Lipshultz1,2

1Children’s Hospital of Michigan, Detroit, Michigan, USA,2Wayne State University, Detroit, Michigan, USA




Evolution and drug resistance in cancer.

Year:

Session type: ,

Ultan McDermott1

1Wellcome Trust Sanger Institute, Hinxton, UK


Integration of germline genetic information can improve cancer diagnosis, treatment and prevention

Year:

Session type: ,

Nazneen Rahman1,2

1Institute of Cancer Research, London, UK,2Royal Marsden, London, UK


The value of genomics in rare cancers.

Year:

Session type: ,

Ultan McDermott1

1Wellcome Trust Sanger Institute, Hinxton, UK


Treatment: How should we treat our patients who develop cardiovascular toxicity? How could we have prevented it?

Year:

Session type: ,

Chris Plummer1

1Freeman Hospital, Newcastle upon Tyne, UK




Translating novel diagnostic and therapeutic radiopharmaceuticals into the clinic”

Year:

Session type: ,

Wim Oyen1,2

1The Institute of Cancer Research, London, UK,2The Royal Marsden NHS Foundation Trust, London, UK


Therapeutic Implications of DNA repair defects in Metastatic Prostate Cancer

Year:

Session type: ,

Johann de Bono1,2

1The Institute of Cancer Research, London, UK,2Royal Marsden, London, UK




Tracking tumour evolution with clonal assays – mutation order matters.

Year:

Session type: ,

David Kent1,2

1Wellcome Trust/ MRC Cambridge Stem Cell Institute, Cambridge, UK,2Department of Haematology University of Cambridge, Cambridge, UK


Genomic analysis of circulating tumour DNA: pushing the limits for cancer applications

Year:

Session type: ,

Nitzan Rosenfeld1,2

1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK,2Inivata Ltd., Cambridge, UK


The future of radiation therapy for pancreatic and liver malignancies

Year:

Session type: ,

Theodore Lawrence1

1College of Medicine, University of Michigan, Michigan, USA


“Rethinking” Cancer as a Complex Adaptive System”

Year:

Session type: ,

Anna Barker1

1Complex Adaptive Systems Institute, Arizona, USA


Promoting physical activity among people living with advanced cancer

Year:

Session type:

Matthew Maddocks1

1King’s College London, London, UK


Genomic tests to personalized therapy of patients with metastatic breast cancer

Year:

Session type: ,

fabrice andre1

1gustave roussy, villjuif, France




Reducing exposure to alcohol to reduce cancer risk.

Year:

Session type: ,

Peter Anderson1

1Newcastle University, Newcastle, UK


Using the Patient care Outcome Scale (POS) in palliative care and oncology: international experiences from research, clinical practice and education

Year:

Session type: ,

Irene Higginson1

1King’s College London, London, UK




Understanding genome organisation: using HiC data to interpret gene regulation and non-coding mutations

Year:

Session type: ,

Nicholas Luscombe1

1The Francis Crick Institute, London, UK


“Intravital imaging reveals how stroma dictates heterogeneous responses to targeted therapy”

Year:

Session type: ,

Erik Sahai1

1The Francis Crick Institute, London, UK


Molecular Risk Stratification for Aspirin Chemoprevention

Year:

Session type: ,

Andrew Chan1

1Massachusetts General Hospital, Boston, MA, USA


Changing the paradigm for therapeutic progress for rare tumors: SPECTArare “Optimizing molecular profiling technologies through partnerships”

Year:

Session type: ,

Denis Lacombe1

1EORTC, Brussels, Belgium


Selective internal radiotherapy: microdosimetry, clinical research and patient advocacy

Year:

Session type:

RICKY SHARMA1,2

1University of Oxford, Oxford, UK,2CRUK-MRC Oxford Institute for Radiation Oncology, Oxford, UK